Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 52: 795-796, 2006; 10.1373/clinchem.2006.068411
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alpert, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alpert, J. S.
(Clinical Chemistry. 2006;52:795-796.)
© 2006 American Association for Clinical Chemistry, Inc.


Editorials

Will the Real Myocardial Infarction Please Stand Up?

Joseph S. Alpert

University of Arizona Health Science Center, 1501 North Campbell Avenue, Tucson, AZ 85724-5035, E-mail jalpert@email.arizona.edu

The first 20% of the full text of this article appears below.

Defining a disease is a process whereby physicians and clinical scientists are able to place a label on a specific pathologic entity. If this label is used carefully, it will characterize that disease process to facilitate future interactions between the patient and the healthcare system. Labeling a patient with a specific diagnosis has important implications for that person with respect to his or her relationship to the rest of society. For example, when a patient is labeled as having suffered a myocardial infarction, that individual’s ability to hold or perform certain jobs (e.g., airline pilot) is altered. He or she may also become eligible to participate in a variety of clinical experiments aimed at improving either the diagnosis or the treatment of patients with myocardial infarction. Unfortunately, clinicians and clinical investigators often define the same disease differently. Furthermore, different clinicians may use different definitions of myocardial infarction. For example, characteristics used to define myocardial infarction in one city or country may be interpreted differently by physicians in another city or country, thereby rendering comparisons between cities or countries difficult if not impossible. In a similar fashion, the definition of myocardial infarction in one international study may differ from that used in another clinical trial. This makes it very difficult to compare the results of different pharmacologic, interventional, . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
CirculationHome page
N. I. Parikh, P. Gona, M. G. Larson, C. S. Fox, E. J. Benjamin, J. M. Murabito, C. J. O'Donnell, R. S. Vasan, and D. Levy
Long-Term Trends in Myocardial Infarction Incidence and Case Fatality in the National Heart, Lung, and Blood Institute's Framingham Heart Study
Circulation, March 10, 2009; 119(9): 1203 - 1210.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
A. B. Rosen, D. M. Cutler, D. M. Norton, H. M. Hu, and S. Vijan
The Value Of Coronary Heart Disease Care For The Elderly: 1987-2002
Health Aff., January 1, 2007; 26(1): 111 - 123.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.